Home/Pipeline/Partner mRNA Product

Partner mRNA Product

Undisclosed

Phase I/IIActive - Dosing Initiated

Key Facts

Indication

Undisclosed

Phase

Phase I/II

Status

Active - Dosing Initiated

Company

4basebio

About 4basebio

4basebio is an innovation-led biotechnology company with a mission to redefine genetic medicine by providing superior, synthetic DNA starting materials. Its core achievement is the development of the TruePrime® enzymatic platform, which enables faster, safer, and more scalable production of DNA compared to conventional bacterial fermentation. The company's strategy is dual-pronged: operating as a high-value supplier of GMP-grade synthetic DNA to pharmaceutical partners and developing its own non-viral delivery platform for therapeutic payloads. A key recent milestone is the entry of a partner's mRNA product, using 4basebio's opDNA®, into a Phase I/II clinical trial following FDA IND approval.

View full company profile

Therapeutic Areas

Genetic Medicine Infectious Disease (Vaccines)

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active